WO2013002428A1 - Composition pour améliorer et empêcher le ronflement - Google Patents

Composition pour améliorer et empêcher le ronflement Download PDF

Info

Publication number
WO2013002428A1
WO2013002428A1 PCT/KR2011/004656 KR2011004656W WO2013002428A1 WO 2013002428 A1 WO2013002428 A1 WO 2013002428A1 KR 2011004656 W KR2011004656 W KR 2011004656W WO 2013002428 A1 WO2013002428 A1 WO 2013002428A1
Authority
WO
WIPO (PCT)
Prior art keywords
snoring
composition
alum
tannin
present
Prior art date
Application number
PCT/KR2011/004656
Other languages
English (en)
Korean (ko)
Inventor
윤기병
Original Assignee
Yoon Ki-Byong
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoon Ki-Byong filed Critical Yoon Ki-Byong
Priority to PCT/KR2011/004656 priority Critical patent/WO2013002428A1/fr
Publication of WO2013002428A1 publication Critical patent/WO2013002428A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/79—Schisandraceae (Schisandra family)
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
    • A61K36/234—Cnidium (snowparsley)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/34—Campanulaceae (Bellflower family)
    • A61K36/346—Platycodon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants

Definitions

  • the present invention constricts the muscles or mucous membranes of the throat around the throat, so that the mucous membrane of the neck or the study area around the throat is sagging or the tonsils are enlarged during sleep.
  • the present invention relates to a composition for improving and preventing snoring, and more particularly, to a composition for improving and preventing snoring, comprising tannin.
  • the composition of the present invention provides tablet and candy-like compositions for snoring improvement, including functional ingredients such as alum, Schizandra chinensis, Bellflower, Magmundong, Cheongung.
  • snoring is a noise phenomenon caused by the friction between the air and the upper airway mucosa when the air is not easily entered due to narrowing around the upper airway during breathing, and is a symptom mainly at bedtime.
  • a flexible tissue such as the palate, neck, tonsils, tongue, etc.
  • the snoring phenomenon is hardly seen because the muscles around the pharynx maintain their positions and open the upper airway.
  • snoring symptoms do not sleep well by the person sleeping and cause sleep respiratory disorders, as well as damage to the family or people around them due to noise. Therefore, in the past, snoring was not particularly regarded as a disease, but recently, snoring is also recognized as a disease.
  • snoring or sleep apnea rapidly reduces or stops the amount of oxygen supplied to the human body through breathing, resulting in an abnormally fast heart rate and rough blood flow that can damage blood vessels and cause various diseases.
  • the main cause of hypertension is snoring, snoring is 3 times higher in the incidence of diabetes and 10 times higher in the incidence of diabetes, and snoring is 75% of obese people with severe erectile dysfunction, especially When a child snores, it is about 20 times lower than the average IQ, and 66% of male drivers who have had a traffic accident are snorers.
  • Sleeping sideways can prevent the structures of the throat from slipping back and block the air passages, while drugs such as alcohol, sedatives, sleeping pills and antihistamines slow and shallow the breath and relax the muscles around the throat more than usual. Reducing these drugs can also help reduce snoring and sleep apnea. You can also reduce snoring by losing weight and doing regular exercises to keep your muscles more elastic and boost your lungs.
  • this method cannot be a fundamental treatment, and even if it is treated, the snoring can be passed for a very long time, so the patient will have to take longer discomfort than other methods that can be treated in a short period of time. In case it would make sense.
  • This surgery has the effect of preventing the snoring and sleep apnea to some extent by expanding the airway, but requires a general anesthesia and hospitalization for one to two days after the operation. In addition, a few weeks after surgery, sore throat pain should eat a soft food.
  • Another surgical method is to remove the entire breast and part of the palate using a laser. This surgery can be done only with local anesthesia, and in some cases, the operation may be repeated one or more times with a few weeks interval.
  • the above surgical methods may cause serious problems that may cause complications such as food entering the nose during meals, negative changes, infections, paresthesia of the tongue, bleeding, etc., so care must be taken, and sometimes do not improve after surgery There is also.
  • the method of using a breathing aid Mainly used in developed countries for the treatment of respiratory disorders, it is a method of forcibly pushing air into the airways during sleep (Continuous Positive Air Pressure). This method is excellent in terms of effectiveness, but the patient has to be inexpensive to blow the air, and the mask must be worn in the mouth and nose during sleep, which makes the user feel uncomfortable.
  • the present invention is to solve the problems described above, in view of the reality that many people are experiencing snoring symptoms, and the damage caused by snoring phenomenon is increasing, more convenient and lower cost to side effects It is an object of the present invention to provide a composition for snoring improvement and prevention that can improve and prevent snoring without concern. In addition, there is another object to provide a composition for snoring improvement and prevention that can simultaneously solve the serious problems associated with snoring, sleep apnea, erectile dysfunction, and sleep disturbance.
  • the present invention provides a composition for snoring improvement and prevention, comprising tannin (tannin).
  • the composition of the present invention provides tablet and candy-like compositions for snoring improvement, including functional ingredients such as alum, Schizandra chinensis, Bellflower, Magmundong, Cheongung.
  • the composition of the present invention is a tablet and candy composition for preventing snoring containing tannin, which is taken 1 to 3 hours before bedtime, and is very simple to use, easy to carry, and has no side effects, and is used at low cost. This has a possible effect. In addition, there is an effect that can simultaneously solve the sleep apnea and sleep disturbance accompanying snoring without side effects.
  • the present invention provides a snoring improvement and prevention composition comprising a tannin (tannin).
  • the composition may include 0.1 to 10% by weight of tannin, and preferably 0.5 to 5% by weight, based on the total weight of the composition.
  • the composition may further include alum.
  • the composition may include 0.1 to 10% by weight of the alum, preferably 0.5 to 5% by weight, based on the total weight of the composition.
  • the weight ratio of the tannin and alum in the present invention may be 1: 0.1 to 10.
  • the composition may further comprise one or more selected from Schizandra chinensis, bellflower, pulmonary dong and cheongung.
  • the composition of the present invention relates to a snoring improvement and prevention composition characterized in that it contains tannin (tannin), and further comprises a snoring symptom, including Schisandra chinensis, bellflower, pulmonary dong, cheongoung, etc.
  • the present invention relates to a functional composition capable of alleviating the suffering of people with disabilities.
  • Tannin which is the main component of the composition of the present invention, is an aromatic compound having a large number of phenolic hydroxyl groups, although the constituent components are separated into the crystalline phase as a single substance, most of them are a mixture of several kinds of substances, white or Obtained as a pale brown monolithic powder. It is a kind of polyphenol with a very bitter taste. It is synthesized by plants and precipitated by binding to protein, and the molecular weight of tannin is more than 500 to 20,000.
  • tannins There are two representative classification of tannins.
  • One method is to classify into hydrolyzable tannins, which are hydrolyzed upon heating with dilute acid to produce gallic acid or erratic acid, and condensed tannins that polymerize to produce red or brown precipitates of probafen.
  • galactanine is mainly produced, and galaxanthin is produced, called eraditannin.
  • Many of them are composed of sugars (usually glucose) and esters of one or several phenolcarboxylic acids, and are hydrolyzed by tanases.
  • Pyrogalol tannins contain tannins, such as stalks, chestnuts, oaks, and balonia, as well as gall bladder and gluttony, and generally have strong convergence. It becomes blue by iron alum solution and then turns black, and bromine water does not produce a precipitate but becomes blue by lime water.
  • the catechol system contains tannins such as mangroves, oak (bark), mimosa (wattle), kepraco, gambia, and generally has low astringent properties. In addition, it turns green by black iron and then turns black. It precipitates by bromine water and does not develop by lime water.
  • the distribution in the plant system is very wide, usually in less ripe fruits or seeds, and tends to decrease with maturity. This may indicate that tannins are metabolizable, but their physiological function is unknown.
  • Imported tannin extract is mainly used in Korea.
  • the production of blue black ink using blue iron by reacting with iron (III) salt in addition to skin repellent, separation or quantification of metal ions using metal ions to produce colored precipitates Tannin acid, which is purified from gallotanine, is astringent, hemostatic agent, and albumin tannin that combines egg white and tannic acid.
  • Tannins can significantly improve or prevent the sound of snoring (snoring) through throat and mucosal contraction around the throat when the mucous membrane of the throat or the periphery of the study area is sagging or the tonsils are enlarged and the airway narrows. Can be.
  • Alum which is another main component of the composition of the present invention, is a double salt formed by sulfate of aluminum sulfate and monovalent metal. Alkali metals other than lithium, potassium, ammonium, etc. are used as the monovalent metal. Double salts refer to salts in which two or more salts combine, and the ions belonging to the salts do not form polyatomic ions such as complex ions, but exist as independent ions.
  • Alum is also known as alum and has the general formula of MAl (SO 4 ) 2 .12H 2 O or M 2 SO 4 .Al 2 (SO 4 ) 3 .24H 2 O. M is a monovalent metal.
  • ammonium alum (NH 4) Al (SO 4) 2 ⁇ 12H 2 O).
  • a case where other trivalent metal ions such as Ti, V, Cr, Mn, Fe, Co, Rn, Ir, Ga, In are substituted in place of aluminum is also referred to as alum in a broad sense. It is named after each metal ion. For example, (NH 4 ) Fe (SO 4 ) 2 .12H 2 O is called ammonium-iron alum.
  • alum crystals dissolve in water. When the crystal is heated, it is dissolved in the crystal water to form a solution.
  • Most of the alum we talk about are potassium alum. Potassium alum is used in coagulants or mordants, and mordants are materials that help dye well by connecting dyes with the fibers to be dyed. This is why the use of alum is used to paint balsam nails.
  • Bovine plaque dehydrated by heating potassium alum is used as an astringent that has the effect of suppressing hemostasis or diarrhea. Alum also improves and prevents snoring by contracting muscles that are severely relaxed during sleep, and combines with tannins to show excellent effects in improving and preventing snoring symptoms.
  • Tannins or alums which are compositions of the present invention, can be administered in known pharmaceutical dosage forms.
  • the dosage of tannin or alum can vary depending on a number of factors, including the age of the patient, the severity of the pathology and the patient's past history and are always within the discretion of the attending physician, but generally the full dosage range of tannin or alum Is 1 to 1000 mg / day, preferably 5 to 200 mg / day, more preferably 20 mg / day, which may be administered in two or more divided doses, but administered about 1 to 3 hours before bedtime improves snoring during sleep. And a prophylactic effect.
  • the weight ratio of tannin and alum is set to 1: 0.1 to 10 to improve synergistic effects due to mutual coupling.
  • compositions for use in the present invention are known pharmaceutical forms for such administration, such as tablets, capsules, granules, syrups and aqueous or oily suspensions.
  • Excipients used in the preparation of such compositions are excipients known in the pharmaceutical and food arts.
  • Tablets may contain active compounds and fillers (e.g. calcium phosphate), disintegrants (e.g. corn starch), lubricants (e.g. magnesium stearate), binders (e.g. microcrystalline cellulose or polyvinylpyrrolidone), and mixtures thereof. It can be prepared from mixtures with any other ingredients known in the art that can be purified by known methods. Tablets may be formulated in a manner known to those skilled in the art for sustained release of the tannins and / or alum of the invention.
  • active compounds and fillers e.g. calcium phosphate
  • disintegrants e.g. corn starch
  • lubricants e.g. magnesium stearate
  • binders
  • conventional additives that may be added in the production of other foods (candy, etc.) may be added. More specifically, by adding the tannin 0.01 to 5% by weight and the alum 0.01 to 5% by weight relative to the total weight of the candy can be prepared candy containing tannin and alum.
  • Schisandra chinensis an additional composition component of the present invention, protects lung function, attenuates chronic bronchitis and pharyngitis sputum, promotes spermatogenic bile branches, and schizolic acid of Schisandra chinensis removes the mucous membranes that block the passage of the airways. Let's do it.
  • the bellflower is a perennial herb belonging to the Camphoraceae
  • the main pharmacological component is triterpenoid-based saponin, which subsides swollen tonsils with strong antioxidant activity, acute bronchitis, pneumonia, And diseases such as asthma.
  • Macmundong an additional composition component of the present invention, is a perennial herb of the Liliaceae lily family, enhances pulmonary function of tuberculosis, replenishes the pulmonary fluid and is used for respiratory diseases and chronic sore throat.
  • Macmundong has various medicinal effects and almost no side effects, so it is easy to use and shows excellent efficacy even in chronic marine diseases.
  • the scholastic arch the additional composition component of the present invention, has been found to have a coercive action, a contraction action, and an antifungal action in pharmacological experiments. It is used to help the circulation of hot and warm celery and to draw tendons.
  • tannin and alum can be added one or more selected from Schizandra chinensis, Bellflower, Magmundong, and Cheongung, and in Schisandra chinensis, Bellflower, Mcmundong and Cheongung in consideration of the improvement effect of snoring and tannin and / or alum.
  • the at least one total addition range selected may be 1-1000 mg / day, preferably 5-200 mg / day, more preferably 10 mg / day.
  • Tannin and alum purchased from a specialized chemical purchaser (Shin Won Trading Co.) was prepared, and a tablet-type snoring improvement and prevention composition was prepared by a method of preparing a conventional tablet.
  • a tablet was prepared in the same manner as in Example 1, except that only the contents of tannin and alum were used to prepare a tablet type snoring improvement and prevention composition (see Table 1 below).
  • Example 1 (Unit: mg) division Tannins alum Remarks
  • Example 2 40 0 The content of the remaining excipients, etc. is the same as in Example 1
  • Example 3 35 5
  • Example 4 30 10
  • Example 5 25 15
  • Example 6 15
  • Example 7 10
  • Example 8 5 35
  • Example 9-18 Preparation of a Tablet Composition Containing Functional Ingredients More
  • Tablets were prepared in the same manner as in Example 1, but tablets were prepared by adding Schizandra chinensis, Bellflower, Magmundong, Cheongung, in addition to tannin and alum, which are the main components of the composition (see Table 2 below).
  • Example 9 10 0 0 0
  • the content of the remaining excipients, etc. is the same as in Example 1
  • Example 10 0 10 0 0 Example 11 0 0 10 0
  • Example 12 0 0 0 10
  • Example 13 10 10 0 0
  • Example 14 10 10 0
  • Example 15 10 10 10
  • Example 16 5 5 5 5
  • Example 17 20
  • 20 20
  • Example 18 30
  • 30 30
  • Tablets were prepared in the same manner as in Example 1, except that both tablets of tannin and alum were prepared.
  • tannin and alum were added by adding 0.2% by weight of tannin and 0.2% by weight of alum, and a composition for improving snoring and preventing snoring was prepared by a conventional method of preparing candy.
  • the subjects of the experiment were selected to test the snoring improvement and prevention effect on the participants with snoring symptoms using the tablet for snoring improvement and prevention composition prepared in the above examples.
  • the test subjects who participated in this experiment were adult males who had no health problems except snoring symptoms.
  • Example 1 For the selector of Experimental Example 1 was administered a tablet composition prepared by the embodiments of the present invention and observed the results. All the selectors took the tablet-type composition of the present invention 3 hours before bedtime and carried out for 30 days to perform a snoring quantitative analysis.
  • the 20 subjects were divided into five groups and tested.
  • One group of tablets prepared by the method of Example 1, two groups of tablets prepared by the method of Example 2, and three groups of Example 15 The tablets prepared by the method, the tablets prepared by the method of Comparative Example 1 in the fourth group, and the tablets prepared in the method of Comparative Example 2 in the fifth group to examine the experimental results.
  • Decibel (dB) at bedtime was measured as one of the well-known tests for sleep polysomnography, and the noise levels after 30 days of continuous tablets were measured.
  • the sound level meter used TES-1350 (TES electrical electronics).
  • Table 6 Sound level measurement result (unit: dB) division Subject Before taking (0 days) After taking (30 days) 1 group One 97 0 2 95 67 3 90 60 4 97 53 2 groups 5 94 36 6 96 59 7 98 0 8 100 62 3 groups 9 89 10 10 93 0 11 93 54 12 96 39 4 groups 13 97 97 14 94 95 15 99 98 16 96 96 5 groups 17 92 89 18 96 93 19 95 91 20 96 90
  • the group (3 groups) ingesting tablets prepared by addition of tannins or by adding additional functional ingredients such as Schisandra chinensis showed better snoring effect.
  • the group (3 groups) ingesting tablets prepared by addition of tannins or by adding additional functional ingredients such as Schisandra chinensis showed better snoring effect.
  • the selector of Experimental Example 1 was administered to the tablet composition prepared by the embodiments of the present invention and observed the degree of apnea closely related to snoring. All the selectors took the tablet-type composition of the present invention for 30 days three hours before bedtime and conducted a quantitative analysis of the degree of apnea.
  • Example 2 20 subjects were divided into five groups, and the experiment was performed.
  • One group was a tablet prepared by the method of Example 1, and two groups were tablets prepared by the method of Example 2.
  • the tablets prepared by the method of Example 15, the tablets prepared by the method of Comparative Example 1, the group 4 and the tablets prepared by the method of Comparative Example 2 were examined the experimental results.
  • the number of apneas and the degree of drop of arterial blood acid saturation (SpO 2 ) were measured by a known apnea measurement method.
  • the measuring apparatus used LT-200 (made by Fukuda Senshi Co., Ltd.) which is a slip tester.
  • the measured experimental value is a value obtained by measuring the number of apneas during sleep and the degree of SpO 2 drop three times each, and rounding off the average (rounding up to a decimal point).
  • composition of the present invention can be usefully used for the prevention and treatment of snoring, etc., which can be applied to functional foods or medicines, which is also helpful for the profit creation of producers and ultimately contribute to the industrial development of the country. do.

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Food Science & Technology (AREA)
  • Otolaryngology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pour améliorer et empêcher le ronflement, le son (son du ronflement) étant dû à la vibration de la membrane muqueuse par respiration rapide lorsque les muscles ou la membrane muqueuse autour de la gorge relaxée sont contractés, la membrane muqueuse de la luette ou du palais mou autour de la luette étant allongé ou les amygdales et similaires étant agrandies avant le sommeil, et ainsi le tractus respiratoire devenant étroit. De façon plus spécifique, la présente invention porte sur une composition pour améliorer et prévenir le ronflement, contenant de l'acide tannique. De plus, la présente invention concerne une composition pour améliorer et prévenir le ronflement sous la forme d'un comprimé ou d'un bonbon contenant des ingrédients fonctionnels tels que le sulfate d'aluminium, Schizandra chinensis, Platycodon grandiflorus, Liriope platyphylla, Cnidium officinale et similaire.
PCT/KR2011/004656 2011-06-27 2011-06-27 Composition pour améliorer et empêcher le ronflement WO2013002428A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/KR2011/004656 WO2013002428A1 (fr) 2011-06-27 2011-06-27 Composition pour améliorer et empêcher le ronflement

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/KR2011/004656 WO2013002428A1 (fr) 2011-06-27 2011-06-27 Composition pour améliorer et empêcher le ronflement

Publications (1)

Publication Number Publication Date
WO2013002428A1 true WO2013002428A1 (fr) 2013-01-03

Family

ID=47424308

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/004656 WO2013002428A1 (fr) 2011-06-27 2011-06-27 Composition pour améliorer et empêcher le ronflement

Country Status (1)

Country Link
WO (1) WO2013002428A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024177612A1 (fr) * 2023-02-26 2024-08-29 Melikoglu Ahmet Spray d'inhalation et procédé de production

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050111156A (ko) * 2004-05-21 2005-11-24 염동순 코골이 및 숙취 해소 조성물과 그의 제조 방법
US20080124411A1 (en) * 2002-02-15 2008-05-29 Cns, Inc. Throat Spray
KR20100043010A (ko) * 2008-10-17 2010-04-27 윤기병 코골이 개선 및 예방용 조성물

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080124411A1 (en) * 2002-02-15 2008-05-29 Cns, Inc. Throat Spray
KR20050111156A (ko) * 2004-05-21 2005-11-24 염동순 코골이 및 숙취 해소 조성물과 그의 제조 방법
KR20100043010A (ko) * 2008-10-17 2010-04-27 윤기병 코골이 개선 및 예방용 조성물

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024177612A1 (fr) * 2023-02-26 2024-08-29 Melikoglu Ahmet Spray d'inhalation et procédé de production

Similar Documents

Publication Publication Date Title
US10105408B2 (en) Traditional Chinese medicine composition and preparation method and use thereof
Wu et al. Thirst relief effect of 0.75% citric acid spray during the anesthesia recovery period: a randomized controlled trial
KR101122703B1 (ko) 코골이 개선 및 예방용 조성물
CN100579557C (zh) 银贝止咳颗粒
WO2013002428A1 (fr) Composition pour améliorer et empêcher le ronflement
CN103751508B (zh) 一种用于围手术期口腔护理的药物及其制备方法
CN106038965A (zh) 一种治疗喉咙病症的中药组合物
CN110025724A (zh) 一种麦冬须根清肺饮组合物
CN102552657B (zh) 一种用于治疗鸡新城疫病的中药组合物
CN101732500A (zh) 一种预防和治疗急慢性咽炎、咽喉炎的药物
KR100852745B1 (ko) 코골이 및 수면무호흡증 완화를 위한 윤활성 생약 조성물
CN110327437B (zh) 治疗慢性腹泻的中药及其制备方法
CN106389962A (zh) 一种防治羔羊大肠杆菌病的中药组合物及其制备方法和应用
CN100556442C (zh) 用于治疗感冒的药
CN108653552B (zh) 一种清肺止咳中药
CN105213991A (zh) 用于治疗胃食管反流病的中药组合物
CN104189076B (zh) 一种治疗小儿寒性哮喘的中药贴及其制备方法
CN118105454B (zh) 一种用于治疗小儿呕吐的药物组合物及其制剂和应用
RU2361599C1 (ru) Фармацевтическая композиция, обладающая седативным и анксиолитическим действием
JP4726268B2 (ja) 医薬組成物
Boyd et al. Candida infection of a persistent palatal ulcer in a 20‐month‐old child
CN104491504A (zh) 一种治疗悬饮症的中药制剂
CN115025182A (zh) 一种治疗呼吸道病毒感染的中药制剂
CN103301437B (zh) 一种增加肠胃功能的中成药及其制备方法
CN103908472A (zh) 一种治疗口腔溃疡含片及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11868803

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205 DATED 27-05-2014)

122 Ep: pct application non-entry in european phase

Ref document number: 11868803

Country of ref document: EP

Kind code of ref document: A1